HeartSciences reports no FY2025 revenue, $1.1M cash; advances MyoVista platform

HeartSciences Inc.

Zero revenue for fiscal year ended April 30, 2025; cash and equivalents $1.1M, shareholders' equity $0.2M.
Raised $3.1M gross in Reg A+ offering post-year-end; converted $0.9M debt to equity.
Launched MyoVista Insights cloud software platform in May 2025 at early adopter sites.
MyoVista wavECG device nearing FDA 510(k) submission; CMS approved $128/test reimbursement for AI-ECG algorithms.
FDA Breakthrough Device designation for aortic stenosis algorithm; 44 granted patents worldwide.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.